The Latest Breaking News from Sickle Cell Disease

Fewer than half of children in the United States with sickle cell disease get a needed screening for stroke, and only about half or fewer get a treatment that can help with pain and anemia.

A study of U.S. children with sickle cell disease found fewer than half get a needed screening for stroke, a common complication

September is National Sickle Cell Awareness Month. The blood disorder occurs among about one of every 365 Black births and one of every 16,300 Latino births, according to the U.S. Centers for Disease Control and Prevention.

Sickle cell disease affects approximately 15,000 people in the UK. But what is it and what are the early signs to spot in children?

As a child, Lea Kilenga was ostracised because of her sickle cell disease. Now she is a champion for others

Across 10 countries almost half those surveyed say they were treated like drug addicts and more than third believe their race influenced poor care

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Most of the global cases of sickle cell disease are diagnosed in African countries. The Economist Intelligence Unit – the research and analysis division of the Economist media group – estimated that in 2020 the total annual cost of treatment and impact on the economy of sickle cell disease across…

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS)  Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…